Rheumatoid Arthritis (RA) - Competitive Landscape

Rheumatoid Arthritis (RA) - Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in RA therapeutics.

• More than 13 million diagnosed prevalent cases of RA are anticipated in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for RA.
• There are 19 leading marketed drugs for the treatment of RA.
• There are 13 drugs in pre-registration stage, including innovator products and biosimilars.
• Commercial sponsors have led the clinical trials space for RA over the past 10 years, with AbbVie sponsoring the highest number of trials overall (61 trials), followed by Pfizer (48 trials) and Boehringer Ingelheim (46 trials).
• In the Asia-Pacific and North America regions, partnership was the most common type of deal, while acquisition was the most common type of deal in Europe. In South America and in Africa, the most common type of deal was licensing agreements.

Scope

GlobalData’s RA: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the RA market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.